10-Q · May 7, 2026
Iovance Biotherapeutics reported strong Q1 results, with total revenue increasing to $71.4 million, up 45% from $49.3 million in the prior year. The company continues to expand its commercial efforts for Amtagvi® and…
10-Q · Filed November 5, 2026 · Our reading of the company's report
The latest report
Iovance delivered a strong Q3 2026 operating result, with revenue of $121.469 million, approximately 60% gross margin and diluted EPS of $(0.05), all improving versus Q2 2026 and Q3 2025. Growth was led by approximately…
Iovance delivered a strong Q3 2026 operating result, with revenue of $121.469 million, approximately 60% gross margin and diluted EPS of $(0.05), all improving versus Q2 2026 and Q3 2025. Growth was led by approximately $102 million of U.S. Amtagvi revenue, while the company maintained full-year 2026 revenue guidance of $410 million to $420 million rather than raising it. Liquidity totaled $382.3 million at September 30, 2026 and is expected to fund at least 12 months of planned operations, but management expects additional capital will be needed to complete development programs and expand manufacturing.
How much of each revenue dollar the business keeps.
One point per quarterly or annual filing. Both margins are shares of that report's revenue.
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Q3 2026 revenue was $121.469 million, up $22.469 million, or 22.7%, from $99 million in Q2 2026 and up $54.469 million, or 81.3%, from $67 million in Q3 2025. Revenue exceeded consensus of $115.987 million by $5.482 million.
U.S. Amtagvi revenue was approximately $102 million in Q3 2026, representing the primary driver of quarterly product revenue growth.
Gross margin was approximately 60% in Q3 2026, up from 56.1% in Q2 2026 and 43.0% in Q3 2025, an improvement of approximately 3.9 and 17.0 percentage points, respectively.
Diluted EPS was $(0.05), improving by $0.06 from $(0.11) in Q2 2026 and by $0.20 from $(0.25) in Q3 2025; EPS also beat the $(0.09) consensus estimate by $0.04.
The company reported $382.3 million of cash, cash equivalents, short-term investments and restricted cash as of September 30, 2026, including $57.9 million of cash and cash equivalents, $318.4 million of short-term investments and $6.0 million of restricted cash.
Management stated that available funds are expected to cover anticipated operating expenses and capital expenditures for at least the next 12 months, while also stating that completing product development and expanding the iCTC will require spending beyond currently available funds.
The company had an accumulated deficit of $2.9 billion and incurred a net loss of $148.6 million in the first nine months of 2026. Management also stated that available funds may not be sufficient to execute the full business plan, including iCTC expansion, and that no committed source of additional capital exists.
The company sold all shares available under its 2025 Sale Agreement, which had provided for up to $350.0 million of common-stock sales, and the agreement terminated as of September 30, 2026. This removes that identified financing channel while the company anticipates spending more than currently available funds.
Manufacturing was centralized at the iCTC after the company ended manufacturing activities at Minaris in January 2026. The filing states that failure of the iCTC to meet production requirements could require qualifying new contract manufacturers, resulting in additional costs and delays in meeting demand for Amtagvi and product candidates.
Full-year 2026 total product revenue guidance of $410 million to $420 million was maintained. Management expects gross-margin improvements to continue, excluding occasional one-time items.
Iovance Biotherapeutics reported strong Q1 results, with total revenue increasing to $71.4 million, up 45% from $49.3 million in the prior year. The company continues to expand its commercial efforts for Amtagvi® and…
Iovance is shifting from development to commercialization with Amtagvi® (lifileucel) as its primary commercial product and Proleukin® as a complementary product. The company reports improving commercial metrics and…
Iovance reported Q3 2025 product revenue of $67.455M (up from $58.555M in Q3 2024) and delivered EPS of $(0.25) versus $(0.28) a year ago. Gross margin declined to ~43.0% from 46.2% y/y, while operating loss remained…
Iovance reported product revenue of $59.95M in Q2 2025 (vs. $31.11M in Q2 2024), driving total six-month revenue of $109.28M. Profitability remains challenged: gross margin is only 5.5% and operating margin is -189.8%,…
Totals from the last full session. Insider and politician figures cover 90 days.
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.
The free pages stop at the last full session. Trader shows every trade as it prints.